Research Article

A combination of methylation and protein markers is capable of detecting gastric cancer detection by combined markers

https://orcid.org/0000-0003-4769-8664

Department of General Surgery II, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Jianlin Song

Department of General Surgery II, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Tongmin Wang

Department of General Surgery II, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Wenchuan Zhu

Department of General Surgery II, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Liangyu Zuo

Department of General Surgery II, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Jinzhi Wu

Department of General Surgery II, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Jianhui Guo

**Author for correspondence: Tel.: +86 138 8816 6669;

E-mail Address: jiguo@ufl.edu

Department of General Surgery II, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Xiaochun Yang

*Author for correspondence: Tel.: +86 158 0882 5607;

E-mail Address: blackstone502@163.com

Department of Ophthalmology, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650032, PR China

Search for more papers by this author

Published Online:11 Oct 2021https://doi.org/10.2217/epi-2021-0080

View article

Abstract

Aim: This study aimed to validate a combination of mSEPT9, mRNF180 and CA724 for gastric cancer (GC) detection. Patients & methods: The performance of mSEPT9, mRNF180 and CA724 was examined in a prospective cohort study with 518 participants (151 with GC, 56 with atrophic gastritis, 87 with other gastrointestinal diseases and 224 with no evidence of disease). Results:mSEPT9, mRNF180 or CA724 alone detected 48.3, 37.1 and 43.1% of GC, respectively. The combination of mSEPT9 and mRNF180 detected 60.3% of GC, and the combination of all three markers detected 68.6% of GC. The detection sensitivity of mSEPT9 and mRNF180 was significantly higher for gastric body and in elder subjects. mSEPT9 was correlated with poorer GC survival. Conclusion: The combination of mSEPT9, mRNF180 and CA724 was adequately sensitive for GC detection. The blood mSEPT9 was predictive for GC prognosis.

Lay abstract

Gastric cancer is the most common cancer type in the digestive system. In this study we developed an effective and convenient blood-based test to detect gastric cancer. This test combined a conventional protein test with a newly invented methylation test. We aimed to validate the test and examine its performance using a prospective cohort study. The study showed that the test has promising potential for noninvasive early detection of gastric cancer. We found that single protein or methylation markers detected a proportion of gastric cancer cases, while a combination of these markers exhibited maximal detection capability. Therefore we concluded that the combined test provided adequate efficacy and should be used as a strategy for future gastric cancer detection.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115–132 (2016).
MedlineGoogle Scholar
2. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA724 compared with CEA and CA19-9 in patients with gastric cancer. Dis. Markers 16(3-4), 105–110 (2000).
Medline CASGoogle Scholar
3. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA724 in gastric cancer with peritoneal dissemination. Gastric Cancer 15(2), 154–161 (2012).
Medline CASGoogle Scholar
4. Chen XZ, Zhang WH, Yang K et al. Quantitative comparisons of summary receiver operating characteristics (sROC) curves among conventional serological tumor biomarkers for predicting gastric cancer in Chinese population. Tumour Biol. 35(9), 9015–9022 (2014).
Medline CASGoogle Scholar
5. Jing JX, Wang Y, Xu XQ et al. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Asian. Pac. J. Cancer Prev. 15(23), 10267–10272 (2014).
MedlineGoogle Scholar
6. Liang Y, Wang W, Fang C et al. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA724 in patients with gastric cancer. Oncotarget 7(31), 49565–49573 (2016).
MedlineGoogle Scholar
7. Chen HM, Fang JY. Epigenetic biomarkers for the early detection of gastrointestinal cancer. Gastrointest. Tumors 1(4), 201–208 (2014).
Medline CASGoogle Scholar
8. Sonohara F, Inokawa Y, Hayashi M, Kodera Y, Nomoto S. Epigenetic modulation associated with carcinogenesis and prognosis of human gastric cancer. Oncol. Lett. 13(5), 3363–3368 (2017).
Medline CASGoogle Scholar
9. Song L, Li Y. Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years. Biomark. Med. 11(6), 415–418 (2017).
CASGoogle Scholar
10. Song L, Jia J, Peng X, Xiao W, Li Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis. Sci. Rep. 7(1), 3032 (2017).
MedlineGoogle Scholar
11. Song L, Li Y. SEPT9: a specific circulating biomarker for colorectal cancer. Adv. Clin. Chem. 72, 171–204 (2015).
Medline CASGoogle Scholar
12. Li Y, Song L, Gong Y, He B. Detection of colorectal cancer by DNA methylation biomarker SEPT9 past, present and future. Biomark. Med. 8(5), 755–769 (2014).
CASGoogle Scholar
13. Cheung KF, Lam CN, Wu K et al. Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer 118(4), 947–959 (2012).
Medline CASGoogle Scholar
14. Xie XM, Deng JY, Hou YC et al. Evaluating the clinical feasibility: the direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric cancer. Cancer Biomark. 15(3), 259–265 (2015).
Medline CASGoogle Scholar
15. Deng J, Liang H, Ying G et al. Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer. Oncotarget 5(10), 3173–3183 (2014).
MedlineGoogle Scholar
16. Zhang X, Zhang X, Sun B et al. Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer. Oncol. Lett. 8(4), 1745–1750 (2014).
Medline CASGoogle Scholar
17. Han F, Sun LP, Liu S et al. Promoter methylation of RNF180 is associated with H. pylori infection and serves as a marker for gastric cancer and atrophic gastritis. Oncotarget 7(17), 24800–24809 (2016).
MedlineGoogle Scholar
18. Deng J, Guo J, Guo X et al. Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter. Oncotarget 7(28), 43461–43474 (2016).
MedlineGoogle Scholar
19. Lofton-Day C, Model F, Devos T et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54(2), 414–423 (2008).
Medline CASGoogle Scholar
20. Dietrich D, Jung M, Puetzer S et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLoS ONE 8(12), e84225 (2013).
MedlineGoogle Scholar
21. Powrózek T, Krawczyk P, Kucharczyk T, Milanowski J. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer preliminary report. Med. Oncol. 31(4), 917 (2014).
MedlineGoogle Scholar
22. Paska AV, Hudler P. Aberrant methylation patterns in cancer a clinical view. Biochem. Med. (Zagreb) 25(2), 161–176 (2015).
MedlineGoogle Scholar
23. Matsui S, Kagara N, Mishima C et al. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients. Oncol. Rep. 36(4), 2225–2235 (2016).
Medline CASGoogle Scholar
24. Verdier-Pinard P, Salaun D et al. Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments. Sci. Rep. 7, 44976 (2017).
Medline CASGoogle Scholar
25. Wu Y, Bu F, Yu H et al. Methylation of septin9 mediated by DNMT3a enhances hepatic stellate cells activation and liver fibrogenesis. Toxicol. Appl. Pharmacol. 315, 35–49 (2017).
Medline CASGoogle Scholar
26. Kuo IY, Chang JM, Jiang SS et al. Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. Int. J. Med. Sci. 11(8), 779–787 (2014).
MedlineGoogle Scholar
27. Cao CQ, Chang L, Wu Q. Circulating methylated septin 9 and ring finger protein 180 for noninvasive diagnosis of early gastric cancer. Transl. Cancer Res. 9(11), 7012–7021 (2020).
CASGoogle Scholar
28. Warren JD, Xiong W, Bunker AM et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9, 133 (2011).
Medline CASGoogle Scholar
29. Tóth K, Sipos F, Kalmár A et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE 7(9), e46000 (2012).
Medline CASGoogle Scholar
30. Church TR, Wandell M, Lofton-Day C et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2), 317–325 (2014). •• First report of mSEPT9 assay performance in the screening of the average-risk population.
Medline CASGoogle Scholar
31. Jin P, Kang Q, Wang X et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J. Gastroenterol. Hepatol. 30(5), 830–833 (2015). • First validation of mSEPT9 assay in Chinese population.
Medline CASGoogle Scholar
32. Wu D, Zhou G, Jin P et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J. Mol. Diagn. 18(4), 535–545 (2016). • First validation of mSEPT9 assay in opportunistic screening.
Medline CASGoogle Scholar
33. Song L, Jia J, Yu H et al. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. J. Cancer Res. Clin. Oncol. 143(6), 1093–1101 (2017).
Medline CASGoogle Scholar
34. Song L, Peng X, Li Y et al. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening. Epigenomics 9(5), 599–610 (2017). • First validation of mSEPT9 assay in detecting colorectal adenoma.
CASGoogle Scholar
35. Schmidt B, Liebenberg V, Dietrich D et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10, 600 (2010).
Medline CASGoogle Scholar
36. Schneider KU, Dietrich D, Fleischhacker M et al. Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer 11, 102 (2011).
Medline CASGoogle Scholar
37. Kneip C, Schmidt B, Seegebarth A et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6(10), 1632–1638 (2011).
MedlineGoogle Scholar
38. Dietrich D, Kneip C, Raji O et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int. J. Oncol. 40(3), 825–832 (2012).
Medline CASGoogle Scholar
39. Schmidt B, Beyer J, Dietrich D, Bork I, Liebenberg V, Fleischhacker M. Quantification of cell-free mSHOX2 plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS ONE 10(2), e0118195 (2015).
MedlineGoogle Scholar
40. Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 76(12), 3446–3450 (2016).
Medline CASGoogle Scholar
41. Song L, Chen Y, Gong Y et al. Opportunistic screening and survival prediction of digestive cancers by the combination of blood mSEPT9 with protein markers. Ther. Adv. Med. Oncol. 16(12), 1758835920962966 (2020). •• First study comprehensively investigating the combination of mSEPT9 with protein markers in detecting four digestive cancers.
Google Scholar
42. Chen XZ, Zhang WK, Yang K et al. Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol. Biol. Rep. 39(9), 9031–9039 (2012).
Medline CASGoogle Scholar
43. Tham C, Chew M, Soong R et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer 120(20), 3131–3141 (2014).
Medline CASGoogle Scholar
44. Lee HS, Hwang SM, Kim TS et al. Circulating methylated septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl. Oncol. 6(3), 290–296 (2013).
MedlineGoogle Scholar
45. Schröck A, Leisse A, de Vos L et al. Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients an observational prospective cohort study. Clin. Chem. 63(7), 1288–1296 (2017).
MedlineGoogle Scholar
46. de Vos L, Gevensleben H, Schröck A et al. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients. Clin. Epigenetics 9, 125 (2017).
MedlineGoogle Scholar

Vol. 13, No. 19

Metrics

Downloaded 278 times

History

Received 4 March 2021

Accepted 20 September 2021

Published online 11 October 2021

Published in print October 2021

Information

Keywords

Author contributions

J Xu, J Guo and X Yang designed the study. J Xu, Jianlin S, T Wang, W Zhu, L Zuo and J Hao recruited the subjects. J Xu and J Song collected the samples and liaised with the laboratory. J Xu analyzed the data, made the figures and tables and wrote the manuscript. J Guo and X Yang proofread the manuscript. X Yang submitted the manuscript.

Financial & competing interests disclosure

This study was supported by Yunnan Health Training Special Project of High Level Talents (grant no.: D-2017032). This study was also funded by the Yunnan Digestive Endoscopy Clinical Medical Center Foundation for Health Commission of Yunnan Province (2021LCZXXF-XH04) of (2X2019-01-02). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

Approval was granted for the study by the ethics committees of the First People’s Hospital of Yunnan Province (approval no. KHLL 2019-034). In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Availability of data & materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

PDF download